Fentanyl Screen with Reflex, Random, Urine
Use
Screening for drug abuse or use involving fentanyl and confirmation of fentanyl if present in the screen. The initial immunoassay provides a presumptive screen with high true-negative rate but potential for false positives due to cross-reactivity; a positive screen triggers confirmation by liquid chromatography tandem mass spectrometry (LC‑MS/MS) with quantification. Negative results indicate no fentanyl above ~0.20 ng/mL detected (screen cutoff: 2 ng/mL), while presence of fentanyl above 0.20 ng/mL or norfentanyl above 1.0 ng/mL indicates strong evidence of fentanyl use.
Special Instructions
Not provided.
Limitations
As an immunoassay-based screen, results may yield false positives due to antibody cross-reactivity and false negatives depending on antibody specificity. Biologic factors such as fluid intake can affect urine drug concentration and test sensitivity. Confirmation by LC‑MS/MS is required for positive screens to confirm fentanyl or metabolite presence.
New York Approved
Methodology
Immunoassay
Biomarkers
LOINC Codes
- 59673-4 - fentaNYL Ur Ql Scn
- 59673-4 - fentaNYL Ur Ql Scn
Result Turnaround Time
0-2 days
Related Documents
For more information, please review the documents below
Specimen
Urine
Volume
5 mL
Minimum Volume
2.5 mL
Container
Clean, plastic urine collection container; submission in plastic 5‑mL tube
Collection Instructions
Collect a random urine specimen; no preservative.
Causes for Rejection
All specimens will be evaluated for test suitability.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 14 days |
| Frozen | 14 days |